Study of drug PB2452 in Ticagrelor-Treated Patients with Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure

Age
18 years - 99 years
Gender
All
participants needed
5
Location
1

Brief description of study

The research study is being conducted to test the study drug PB2452 to see if it is safe and will reverse the bleeding effects of Brilinta® (also known as ticagrelor). Candidates must be taking Brilinta® (ticagrelor) or show intake within the past 3 days. They will be considered for participation in the study if they are experiencing uncontrolled or life-threatening bleeding or require urgent surgery where reversal of the antiplatelet effects of the medication Brilinta® (ticagrelor) is required.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Bleeding
  • Age: 18 years - 99 years
  • Gender: All
Updated on 04 Aug 2024. Study ID: 850729
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research